Theranostics 2014; 4(6):614-628. doi:10.7150/thno.8478
Polyacrylamide-Based Biocompatible Nanoplatform Enhances the Tumor Uptake, PET/fluorescence Imaging and Anticancer Activity of a Chlorophyll Analog
1. PDT Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;
2. Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA;
3. Department of Nuclear Medicine, State University of New York, Buffalo, NY 14032, USA.
In this report we demonstrate the outstanding advantages of multifunctional nanoplatforms for cancer-imaging and therapy. The non-toxic polyacrylamide (PAA) nanoparticles (size:18-25 nm) formulation drastically changed the pharmacokinetic profile of the 124I- labeled chlorophyll-a derivative (formulated in 10% ethanol in PBS) with a remarkable enhancement in tumor uptake, and significantly reduced uptake in spleen and liver. Among the various nanoformulations investigated, the 124I- labeled photosensitizer (dose: 0.6142 MBq), and the cyanine dye-nanoparticles (CD-NP) conjugate (dose 0.3 μmol/kg) in combination showed great potential for tumor imaging (PET/NIR fluorescence) in BALB/c mice bearing Colon26 tumors. Compared to free non-labeled photosensitizer, the corresponding PAA nanoformulation under similar treatment parameters showed a remarkable enhancement in long-term tumor cure by PDT (photodynamic therapy) and provides an opportunity to develop a single nanoplatform for tumor-imaging (PET/fluorescence) and phototherapy, a practical “See and Treat” approach.
Keywords: Nanoparticles, photodynamic therapy, Positron Imaging Tomography, Reactive Oxygen species.
Gupta A, Wang S, Marko A, Joshi P, Ethirajan M, Chen Y, Yao R, Sajjad M, Kopelman R, Pandey RK. Polyacrylamide-Based Biocompatible Nanoplatform Enhances the Tumor Uptake, PET/fluorescence Imaging and Anticancer Activity of a Chlorophyll Analog. Theranostics 2014; 4(6):614-628. doi:10.7150/thno.8478. Available from http://www.thno.org/v04p0614.htm